BLI Banque de Luxembourg Investments purchased a new stake in IQVIA Holdings Inc. (NYSE:IQV - Free Report) in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The fund purchased 85,770 shares of the medical research company's stock, valued at approximately $16,939,000.
Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Synergy Asset Management LLC acquired a new position in IQVIA during the 4th quarter worth $33,000. GKV Capital Management Co. Inc. bought a new position in shares of IQVIA in the fourth quarter worth about $39,000. Lee Danner & Bass Inc. acquired a new position in shares of IQVIA during the 4th quarter worth about $44,000. Zions Bancorporation N.A. grew its holdings in IQVIA by 55.2% in the 4th quarter. Zions Bancorporation N.A. now owns 239 shares of the medical research company's stock valued at $47,000 after buying an additional 85 shares during the last quarter. Finally, Versant Capital Management Inc lifted its holdings in shares of IQVIA by 46.0% during the fourth quarter. Versant Capital Management Inc now owns 295 shares of the medical research company's stock worth $58,000 after buying an additional 93 shares during the last quarter. Institutional investors own 89.62% of the company's stock.
IQVIA Price Performance
IQVIA stock traded down $3.12 during midday trading on Friday, reaching $150.17. 804,869 shares of the stock were exchanged, compared to its average volume of 1,728,143. The company's fifty day moving average is $164.60 and its 200-day moving average is $189.07. The company has a debt-to-equity ratio of 2.12, a quick ratio of 0.84 and a current ratio of 0.84. IQVIA Holdings Inc. has a 52 week low of $135.97 and a 52 week high of $252.88. The firm has a market cap of $25.98 billion, a PE ratio of 20.02, a PEG ratio of 1.99 and a beta of 1.34.
IQVIA (NYSE:IQV - Get Free Report) last announced its earnings results on Tuesday, May 6th. The medical research company reported $2.70 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.63 by $0.07. The company had revenue of $3.83 billion during the quarter, compared to analyst estimates of $3.77 billion. IQVIA had a net margin of 8.91% and a return on equity of 28.81%. The firm's quarterly revenue was up 2.5% compared to the same quarter last year. During the same period in the previous year, the business earned $2.54 earnings per share. On average, sell-side analysts forecast that IQVIA Holdings Inc. will post 10.84 EPS for the current year.
Wall Street Analyst Weigh In
A number of brokerages have weighed in on IQV. Mizuho reduced their price target on shares of IQVIA from $242.00 to $210.00 and set an "outperform" rating for the company in a report on Wednesday, April 9th. UBS Group lowered their price target on IQVIA from $255.00 to $185.00 and set a "buy" rating on the stock in a research note on Wednesday. Citigroup reduced their price objective on IQVIA from $225.00 to $210.00 and set a "neutral" rating for the company in a research report on Tuesday, March 4th. Barclays lowered their price objective on IQVIA from $170.00 to $165.00 and set an "equal weight" rating on the stock in a research report on Wednesday. Finally, Robert W. Baird decreased their price target on shares of IQVIA from $195.00 to $161.00 and set a "neutral" rating on the stock in a research note on Wednesday. Eight analysts have rated the stock with a hold rating, sixteen have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus target price of $231.71.
Read Our Latest Research Report on IQVIA
IQVIA Company Profile
(
Free Report)
IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.
See Also
Before you consider IQVIA, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and IQVIA wasn't on the list.
While IQVIA currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.
Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
